Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease

被引:489
作者
Ferrer, I
Rovira, MB
Guerra, MLS
Rey, MJ
Costa-Jussá, F
机构
[1] Hosp Univ Bellvitge, Serv Anat Patol, Inst Neuropathol, Lhospitalet De Llobregat 08907, Spain
[2] Hosp Clin Univ Barcelona, Banc Teixits Neurol, Barcelona, Spain
[3] HGU Hebron, Serv Neurol, Barcelona, Spain
[4] Inst Catala Neurociencies Aplicades, Fundacio ACE, Barcelona, Spain
[5] Inst Catala Neurociencies Aplicades, Fundacio ACE, Unitat Diagnost Transtorms Cognitius & Conducta, Barcelona, Spain
[6] Hosp Barcelona, Barcelona, Spain
[7] Univ Barcelona, Hosp Llobregat, Unitat Neuropatol Expt, E-08007 Barcelona, Spain
关键词
D O I
10.1111/j.1750-3639.2004.tb00493.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
beta-amyloid deposition resembling plaques in Alzheimer's disease (AD), results in a decrease of amyloid burden when compared with non-treated transgenic animals. Immunization with amyloid-beta peptide has been initiated in a randomised pilot study in AD. Yet a minority of patients developed a neurological complication consistent with meningoencephalitis and one patient died; the trial has been stopped. Neuropathological examination in that patient showed meningoencephalitis, and focal atypically low numbers of diffuse and neuritic plaques but not of vascular amyloid, nor regression of tau pathology in neurofibrillary tangles and neuropil threads. The present neuropathological study reports the second case of meningoencephalitis following immunization with amyloid-beta peptide in AD, and has been directed toward exploring mechanisms underlying decreased tau pathology in relation with amyloid deposit regression, and possible molecular bases involved in the inflammatory response following immunization. Inflammatory infiltrates were composed of CD8+,CD4+,CD3+,CD5+ and, rarely, CD7+ lymphocytes, whereas B lymphocytes and T cytotoxic cells CD16, CD57, TIA and graenzyme were negative. Characteristic neuropathological findings were focal depletion of diffuse and neuritic plaques, but not of amyloid angiopathy, and the presence of small numbers of extremely dense (collapsed) plaques surrounded by active microglia, and multinucleated giant cells filled with dense Abeta(42) and Abeta(40), in addition to severe small cerebral blood vessel disease and multiple cortical hemorrhages. Reduced amyloid burden was accompanied by low amyloid-associated oxidative stress responses (reduced superoxide dismutase-1: SOD-1 expression) and by local inhibition of the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) and p38 kinase which are involved in tau phosphorylation. These results support the amyloid cascade of tau phosphorylation in AD regarding phosphorylation of tau dependent on beta-amyloid deposition in neuritic plaques, but not of tau in neurofibrillary tangles and threads. Furthermore, amyloid reduction was accompanied by increased expression of the PA28alpha/beta inductor, and of LMP7, LMP2 and MECL1 subunits of the immunoproteasome in microglial and inflammatory cells surrounding collapsed plaques, and in multinucleated giant cells. Immunoproteasome subunit expression was accompanied by local presentation of MHC class I molecules. Release of antigenic peptides derived from beta-amyloid processing may enhance T-cell inflammatory responses accounting for the meningoencephalitis following amyloid-beta peptide immunization.
引用
收藏
页码:11 / 20
页数:10
相关论文
共 51 条
[1]   Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis [J].
Atzori, C ;
Ghetti, B ;
Piva, R ;
Srinivasan, AN ;
Zolo, P ;
Delisle, MB ;
Mirra, SS ;
Migheli, A .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (12) :1190-1197
[2]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[3]   Alzheimer's disease and oxidative stress: Implications for novel therapeutic approaches [J].
Behl, C .
PROGRESS IN NEUROBIOLOGY, 1999, 57 (03) :301-323
[4]   GSK3β signalling:: Casting a wide net in Alzheimer's disease [J].
Bhat, RV ;
Budd, SL .
NEUROSIGNALS, 2002, 11 (05) :251-261
[5]   Set back to Alzheimer vaccine studies [J].
Birmingham, K ;
Frantz, S .
NATURE MEDICINE, 2002, 8 (03) :199-200
[6]   The proteasome [J].
Bochtler, M ;
Ditzel, L ;
Groll, M ;
Hartmann, C ;
Huber, R .
ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, 1999, 28 :295-+
[7]  
Braak H, 1999, CEREB CORTEX, V14, P475, DOI DOI 10.1007/978-1-4615-4885-014
[8]   ALZHEIMER PATIENTS AND DOWN PATIENTS - ABNORMAL PRESYNAPTIC TERMINALS ARE RELATED TO CEREBRAL PREAMYLOID DEPOSITS [J].
BUGIANI, O ;
GIACCONE, G ;
VERGA, L ;
POLLO, B ;
GHETTI, B ;
FRANGIONE, B ;
TAGLIAVINI, F .
NEUROSCIENCE LETTERS, 1990, 119 (01) :56-59
[9]   Nerve inflammation halts trial for Alzheimer's drug [J].
Check, E .
NATURE, 2002, 415 (6871) :462-462
[10]   The ubiquitin-proteasome pathway: on protein death and cell life [J].
Ciechanover, A .
EMBO JOURNAL, 1998, 17 (24) :7151-7160